KEGG   NETWORK: N00260Help
Entry
N00260                      Network                                

Name
Amplified MET to PI3K signaling pathway
Definition
MET* -> GAB1 -> PI3K -> PIP3 -> AKT -> MTOR
  Expanded
4233v3 -> 2549 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475
Class
nt06214 PI3K signaling
nt06261 Gastric cancer
Type
Variant
Pathway
hsa05226  Gastric cancer
Disease
H00018  Gastric cancer
Gene
4233  MET; MET proto-oncogene, receptor tyrosine kinase
2549  GAB1; GRB2 associated binding protein 1
5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
207  AKT1; AKT serine/threonine kinase 1
208  AKT2; AKT serine/threonine kinase 2
10000  AKT3; AKT serine/threonine kinase 3
2475  MTOR; mechanistic target of rapamycin kinase
Variant
4233v3  MET amplification
Reference
  Authors
Appleman LJ
  Title
MET signaling pathway: a rational target for cancer therapy.
  Journal
J Clin Oncol 29:4837-8 (2011)
DOI:10.1200/JCO.2011.37.7929
Reference
  Authors
Feng Y, Ma PC
  Title
Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer.
  Journal
Cancer Discov 1:550-4 (2011)
DOI:10.1158/2159-8290.CD-11-0289
Reference
  Authors
Kawakami H, Okamoto I
  Title
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
  Journal
Gastric Cancer 19:687-95 (2016)
DOI:10.1007/s10120-015-0585-x

DBGET integrated database retrieval system